- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03157674
Real-World Evidence and Treatment Patterns: Head and Neck Cancer
January 4, 2024 updated by: Bristol-Myers Squibb
This study will be focused on HNC patients who have been diagnosed with HNC between 01-Jan-2013 and 30-Sep-2016.
Study Overview
Study Type
Observational
Enrollment (Actual)
43994
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shibuya-ku
-
Tokyo, Shibuya-ku, Japan, 150-0002
- Local Institution
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients in the Medical Data Vision (MDV) database with a HNC diagnosis will be used to identify eligible subjects by applying the patient inclusion and exclusion criteria.
Description
Inclusion Criteria:
- HNC or undefined histology (not otherwise specified [NOS]) HNC diagnosis from 01-Jan-2013 to 30-Sep-2016 using Japanese disease code
- Age 18 years or older at initial diagnosis of HNC regardless of staging
Exclusion Criteria:
- Diagnosis of another malignancy on or before the initial diagnosis of HNC with the exception of non-melanoma skin cancer and metastatic cancer
- Diagnosis of HNC before 01-Jan 2013 or after 30-Sep-2016
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
HNC patients
HNC patients who have been diagnosed with HNC between 01-Jan-2013 and 30-Sep-2016. |
Non-Interventional
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of patients receiving radiotherapy as anti-cancer treatment
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
Proportion of patients receiving surgery as anti-cancer treatment
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
Proportion of patients receiving chemotherapy as anti-cancer treatment
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
Proportion of patients receiving targeted therapy as anti-cancer treatment
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
Proportion of patients receiving supportive care as anti-cancer treatment
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
Distribution of Treatment History in Head and Neck Cancer (HNC) patients
Time Frame: Approximately 45 months
|
Approximately 45 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Distribution of overall survival (OS) by age
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
|
Distribution of overall survival (OS) by gender
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
|
Distribution of overall survival (OS) by stage
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
|
Distribution of overall survival (OS) by tumor site
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
|
Distribution of overall survival (OS) by treatment regimen
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
|
Number of treatment-limiting adverse events (AEs)
Time Frame: Approximately 45 months
|
Incidence of important treatment-limiting adverse events (AEs) associated with systemic therapies
|
Approximately 45 months
|
|
Number of withdrawals due to AEs
Time Frame: Approximately 45 months
|
Approximately 45 months
|
|
|
Proportion of diagnosis of another malignancy on or before the initial diagnosis of HNC
Time Frame: At Baseline
|
At Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 24, 2016
Primary Completion (Actual)
December 5, 2018
Study Completion (Actual)
April 20, 2020
Study Registration Dates
First Submitted
May 16, 2017
First Submitted That Met QC Criteria
May 16, 2017
First Posted (Actual)
May 17, 2017
Study Record Updates
Last Update Posted (Actual)
January 5, 2024
Last Update Submitted That Met QC Criteria
January 4, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CA209-868
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.